Home LiteratureArticle Details
PMID: 22078169 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Blood-based biomarkers for Alzheimer's disease: plasma Aβ40 and Aβ42, and genetic variants.

Neurobiology of aging ·Vol. 32 Suppl 1 ·2011-12-00 ·Pages S10-9

Mayeux R, Schupf N

Abstract

Identifying a biomarker for Alzheimer's disease that can be obtained from a blood sample has been a goal of researchers for many years. Over the past few years a number of investigators have studied several plasma biomarkers but most frequently plasma amyloid beta (Aβ)40 and Aβ42 while others have explored the use of genetic variants as biomarkers for diagnosis or risk. This review considers the cross-sectional and longitudinal data regarding plasma Aβ40 and Aβ42 as diagnostic biomarkers as well as risk biomarkers. Review of recent genome-wide association studies indicates as many as 10 genetic variants have been associated with susceptibility to Alzheimer's disease (AD). Further analysis suggests that these factors have modest effects on risk and are thus not helpful, as yet, in the diagnosis of disease. Until the function of these genes is understood, their role in risk and diagnosis will remain uncertain. Thus, there are several types of peripheral biomarkers under investigation, but more work is required before they can be deemed clinically useful.

MeSH Terms
Alzheimer Disease/diagnosis,genetics Amyloid beta-Peptides/blood Apolipoprotein E4/genetics Biomarkers/blood Genetic Predisposition to Disease/genetics Genome-Wide Association Study Humans Mutation Peptide Fragments/blood Presenilin-1/genetics Presenilin-2/genetics Risk
Chemicals
Amyloid beta-Peptides Apolipoprotein E4 Biomarkers Peptide Fragments Presenilin-1 Presenilin-2 amyloid beta-protein (40-42)
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Mayeux Richard
Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, the Gertrude H Sergievsky Center, and the Department of Neurology,Psychiatry, and Epidemiology, Columbia University, New York, NY, USA. [email protected]
Schupf Nicole
References (55)
55 references, click to expand
  1. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.
    Neurobiol Aging. 2010 Mar;31(3):357-67 PMID: 18486992
  2. Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome.
    Arch Neurol. 2007 Jul;64(7):1007-13 PMID: 17620492
  3. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE.
    Am J Hum Genet. 2008 Nov;83(5):623-32 PMID: 18976728
  4. Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing.
    Exp Neurol. 2010 Jun;223(2):366-70 PMID: 19664622
  5. A specific amyloid-beta protein assembly in the brain impairs memory.
    Nature. 2006 Mar 16;440(7082):352-7 PMID: 16541076
  6. Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease.
    Nat Genet. 2009 Feb;41(2):192-8 PMID: 19136949
  7. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.
    Neurology. 1984 Jul;34(7):939-44 PMID: 6610841
  8. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk.
    Neurology. 2003 Nov 11;61(9):1185-90 PMID: 14610118
  9. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.
    Nat Genet. 2011 May;43(5):436-41 PMID: 21460841
  10. Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease.
    Am J Hum Genet. 2009 Jan;84(1):35-43 PMID: 19118814
  11. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
    Lancet Neurol. 2006 Mar;5(3):228-34 PMID: 16488378
  12. CSF markers for incipient Alzheimer's disease.
    Lancet Neurol. 2003 Oct;2(10):605-13 PMID: 14505582
  13. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease.
    Arch Gen Psychiatry. 2010 Jul;67(7):739-48 PMID: 20603455
  14. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.
    Arch Neurol. 2007 Mar;64(3):354-62 PMID: 17353377
  15. Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease.
    Arch Neurol. 2008 Jun;65(6):776-85 PMID: 18541797
  16. Plaque-bearing mice with reduced levels of oligomeric amyloid-beta assemblies have intact memory function.
    Neuroscience. 2008 Feb 6;151(3):745-9 PMID: 18155846
  17. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment.
    Dement Geriatr Cogn Disord. 2007;23(5):316-20 PMID: 17374949
  18. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease.
    Nat Genet. 2011 May;43(5):429-35 PMID: 21460840
  19. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease.
    Nat Genet. 2009 Oct;41(10):1088-93 PMID: 19734902
  20. The number of trait loci in late-onset Alzheimer disease.
    Am J Hum Genet. 2000 Jan;66(1):196-204 PMID: 10631151
  21. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.
    Ann Neurol. 2006 Mar;59(3):512-9 PMID: 16372280
  22. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study.
    Lancet Neurol. 2006 Aug;5(8):655-60 PMID: 16857570
  23. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease.
    Ann Neurol. 1999 Sep;46(3):412-6 PMID: 10482274
  24. Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine.
    Neurobiol Aging. 2008 Jan;29(1):1-11 PMID: 17055615
  25. Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment.
    Neurology. 2004 Sep 14;63(5):828-31 PMID: 15365131
  26. Genome-wide association of familial late-onset Alzheimer's disease replicates BIN1 and CLU and nominates CUGBP2 in interaction with APOE.
    PLoS Genet. 2011 Feb;7(2):e1001308 PMID: 21379329
  27. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels.
    Arch Neurol. 2003 Jul;60(7):958-64 PMID: 12873852
  28. Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease.
    Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14052-7 PMID: 18779561
  29. A new clinical scale for the staging of dementia.
    Br J Psychiatry. 1982 Jun;140:566-72 PMID: 7104545
  30. Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study.
    Arch Neurol. 2008 Feb;65(2):256-63 PMID: 18268197
  31. GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers.
    Neuron. 2007 Jun 7;54(5):713-20 PMID: 17553421
  32. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease.
    Nat Med. 1996 Aug;2(8):864-70 PMID: 8705854
  33. Genome screen of late-onset Alzheimer's extended pedigrees identifies TRPC4AP by haplotype analysis.
    Am J Med Genet B Neuropsychiatr Genet. 2009 Jan 5;150B(1):50-5 PMID: 18449908
  34. Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study.
    Neurology. 2008 May 6;70(19):1664-71 PMID: 18401021
  35. Examination of the current top candidate genes for AD in a genome-wide association study.
    Mol Psychiatry. 2010 Jul;15(7):756-66 PMID: 19125160
  36. Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment.
    Neuroimage. 2012 Jan 2;59(1):212-7 PMID: 21824521
  37. Plasma levels of alpha beta peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease.
    Acta Neurobiol Exp (Wars). 2005;65(2):117-24 PMID: 15960295
  38. Biochemical markers in persons with preclinical familial Alzheimer disease.
    Neurology. 2008 Jul 8;71(2):85-92 PMID: 18509095
  39. Role of progranulin as a biomarker for Alzheimer's disease.
    Biomark Med. 2010 Feb;4(1):37-50 PMID: 20387302
  40. Meta-analysis of the association between variants in SORL1 and Alzheimer disease.
    Arch Neurol. 2011 Jan;68(1):99-106 PMID: 21220680
  41. Ten-year change in plasma amyloid beta levels and late-life cognitive decline.
    Arch Neurol. 2009 Oct;66(10):1247-53 PMID: 19822780
  42. Genome-wide analysis of genetic loci associated with Alzheimer disease.
    JAMA. 2010 May 12;303(18):1832-40 PMID: 20460622
  43. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease.
    Arch Neurol. 2008 Jan;65(1):45-53 PMID: 17998437
  44. Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment.
    Neurobiol Aging. 2006 Jun;27(6):904-5 PMID: 16638622
  45. Association of plasma amyloid beta with risk of dementia: the prospective Three-City Study.
    Neurology. 2009 Sep 15;73(11):847-53 PMID: 19752451
  46. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease.
    Nat Genet. 2007 Feb;39(2):168-77 PMID: 17220890
  47. Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer's disease.
    PLoS One. 2009 Aug 07;4(8):e6501 PMID: 19668339
  48. Plasma amyloid beta protein is elevated in late-onset Alzheimer disease families.
    Neurology. 2008 Feb 19;70(8):596-606 PMID: 17914065
  49. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease.
    Nat Genet. 2009 Oct;41(10):1094-9 PMID: 19734903
  50. CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry.
    Brain Res Bull. 2003 Aug 15;61(3):235-42 PMID: 12909293
  51. Selective reductions in plasma Abeta 1-42 in healthy elderly subjects during longitudinal follow-up: a preliminary report.
    Am J Geriatr Psychiatry. 2005 Oct;13(10):914-7 PMID: 16223971
  52. Parental history of Alzheimer disease associated with lower plasma apolipoprotein E levels.
    Neurology. 2009 Sep 1;73(9):681-7 PMID: 19720974
  53. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
    Arch Neurol. 2007 Mar;64(3):343-9 PMID: 17210801
  54. Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease.
    Neurology. 2005 Nov 8;65(9):1402-8 PMID: 16275827
  55. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice.
    Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10837-42 PMID: 12119423
Article Info
Journal
Neurobiology of aging
Abbr.
Neurobiol Aging
ISSN
1558-1497
DOI
10.1016/j.neurobiolaging.2011.09.004
Email
[email protected]
Published
2011-12-00
Pages
S10-9
Language
English
Region
United States
NLM ID
8100437
PMCID
PMC3233700
Subset
IM
Grants
NIA NIH HHS · P01 AG007232-20 · United States
NIA NIH HHS · P50 AG008702 · United States
NIA NIH HHS · P01AG07232 · United States
NIA NIH HHS · P01 AG007232 · United States
NIA NIH HHS · R01 AG037212-03 · United States
NIA NIH HHS · R37 AG015473 · United States
NIA NIH HHS · R01 AG037212 · United States
NIA NIH HHS · P50 AG08702 · United States
NIA NIH HHS · R37AG15473 · United States
External Links
PubMed source DOI: 10.1016/j.neurobiolaging.2011.09.004 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2